CHICAGO, April 1 /PRNewswire/ --
- MOMENTUM Trial Results Presented at the American College of Cardiology Annual Meeting
Orqis(R) Medical Corporation, a medical products company developing and marketing devices to treat heart failure, announced today that the company's MOMENTUM Trial results were presented during the Late Breaking Clinical Trials session at the annual American College of Cardiology (ACC) meeting in Chicago. The MOMENTUM Trial evaluated the percutaneous Cancion System in patients hospitalized with heart failure.
Barry Greenberg, M.D., Director, Advanced Heart Failure Treatment Program, University of California San Diego Medical Center, and National Principal Investigator for the MOMENTUM Trial, presented, "Efficacy and Safety of Continuous Aortic Flow Augmentation in Patients Hospitalized with Acute Decompensated Heart Failure: Results of the MOMENTUM Trial."
"While the MOMENTUM Trial did not meet its primary composite efficacy endpoint, MOMENTUM is a landmark study demonstrating that the Cancion System, in combination with conventional medical (drug) treatment, statistically significantly improved cardiac performance compared with drug treatment alone," stated Dr. Greenberg. He continued, "There has been very little progress in identifying effective new approaches for treating patients with decompensated heart failure and the Cancion System provides physicians with a needed new treatment option."
Mr. Ken Charhut, President and CEO, Orqis Medical, stated, "MOMENTUM proved that the Cancion System significantly improves cardiac performance." He continued, "Orqis' unique aortic flow therapy bridges the gap between medical management and more invasive procedures without ever touching the heart." The Cancion System is currently available in markets outside the U.S.
About Heart Failure
Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over US$33 billion in direct and indirect costs to the U.S. healthcare system each year.
About Orqis Medical Corporation
Orqis Medical Corporation is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System has secured the CE mark. The implantable Exeleras(R) System is in development.
For more information on Orqis Medical, please visit http://www.orqis.com
Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.
Web site: http://www.orqis.com
Media inquiries, Brian McIntee, Director of Marketing, +1-949-268-0184, or Financial inquiries, David Richards, Controller, +1-949-268-7866, both of Orqis Medical Corporation
Comments